Upregulated SFK and MEK activity served as a rationale to test the effect of dual SFKs/MEK inhibition on the survival of an IM‐resistant cell line and IM‐insensitive CML CD34+ cells. The gene discussed is MAP2K7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.